Xencor

Xencor is a clinical-stage biopharmaceutical company focused on the discovery and development of engineered monoclonal antibodies and other protein structures for the treatment of cancer and autoimmune diseases.

The company's proprietary XmAb® technology platform enables the creation of antibody and protein drug candidates with enhanced properties, such as longer half-life, increased potency, and the ability to bind to multiple targets. This platform is the core of Xencor's strategy, allowing for the rapid generation and advancement of a broad pipeline of drug candidates.

Xencor's business model is centered around a hybrid approach of internal development and strategic collaborations. The company advances its own drug candidates through clinical trials while also leveraging its XmAb® platform to create and license drug candidates to major pharmaceutical and biotechnology companies. This dual strategy provides multiple revenue streams, including upfront payments, milestone payments, and royalties from partnered programs, which helps to fund the company's internal research and development efforts.

The company's client base consists of large pharmaceutical and biotechnology firms that license its technology and co-develop drug candidates. Xencor operates in the highly competitive biopharmaceutical market, with a focus on oncology and immunology, two of the largest and fastest-growing therapeutic areas.

Keywords: biopharmaceutical, monoclonal antibodies, oncology, autoimmune diseases, protein engineering, XmAb platform, clinical-stage, drug development, licensing, collaborations